AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
AGIOS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$34.90+3.58 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
88.3%
Operating margin
-873.9%
Net margin
-764.0%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +48.0% | +56.0% | – | -0.9% | |
| Gross profit | +47.5% | +56.1% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -56.4% | -63.0% | -30.2% | |
| Return on assets | -38.2% | -37.5% | -27.9% | |
| Current ratio | 6.33 | 6.74 | 11.46 | |
| Inventory turnover | – | 0.0× | 0.2× | |
| Capex to revenue | 14.2% | – | 8.0% | |
| Diluted shares | 39M | 69M | 58M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Agios Pharmaceuticals generated $1.78B from operations and spent $820.11M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
Generated
$1.78B
Used
$820.11M
Capital expenditure$17.62M2%Dividends$00%Share buybacks$802.49M98%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-764.0%
×Asset turnover0.04×
×Equity multiplier1.08×
=Return on equity, FY2025-30.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -764.0% | 0.04× | 1.08× | -30.2% |
| FY2024 | 1845.9% | 0.03× | 1.11× | 57.3% |
| FY2023 | -1312.6% | 0.02× | 1.14× | -36.8% |
| FY2022 | -1627.8% | 0.01× | 1.12× | -19.4% |
| FY2019 | -349.0% | 0.13× | 1.32× | -62.0% |
| FY2018 | -366.6% | 0.13× | 1.39× | -65.1% |
| FY2017 | -731.6% | 0.07× | 1.68× | -85.7% |
| FY2016 | -284.0% | 0.13× | 1.48× | -56.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$412.78M
- Cash generatingOperating cash flow above zero-$372.98M
- Return on assets improvedROA up on the prior year71.9% → -24.8%
- Earnings backed by cashOperating cash flow above net income-$372.98M vs -$412.78M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.90 → 11.46
- No dilutionShare count did not rise58M → 58M
- Gross margin improvedGross margin up on the prior year88.59% → 88.26%
- More efficientAsset turnover rose0.04 → 0.03